The goal of intragraft gene therapy

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Despite the impressive results of one-year survival rates, organ transplantation still faces major problems. Current anti-rejection drugs reduce systemic immunity nonselectively and increase the risk of infection and cancer on the long term. Theoretically, selective inhibition of alloimmune response can be achieved at the organ level by intragraft transfer of genes with immunomodulatory properties. In the last decade, gene therapy emerged as a new strategy in renal, heart and liver transplantation, showing promising results in experimental animals, almost in controlling acute rejection. The success of gene therapy in the transplant medicine is strongly dependent on the efficiency of the delivery system that allows local transfer and expression of the therapeutic gene in the target organ or tissue. The main findings concerning the suitability of gene therapy in preventing graft rejection will be discussed here.

Original languageEnglish
Title of host publicationContributions to Nephrology
Pages143-150
Number of pages8
Volume146
Publication statusPublished - 2005

Publication series

NameContributions to Nephrology
Volume146
ISSN (Print)03025144

Fingerprint

Genetic Therapy
Graft Rejection
Organ Transplantation
Heart Transplantation
Liver Transplantation
Kidney Transplantation
Immunity
Medicine
Transplants
Gene Expression
Infection
Pharmaceutical Preparations
Genes
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

Tomasoni, S., & Benigni, A. (2005). The goal of intragraft gene therapy. In Contributions to Nephrology (Vol. 146, pp. 143-150). (Contributions to Nephrology; Vol. 146).

The goal of intragraft gene therapy. / Tomasoni, Susanna; Benigni, Ariela.

Contributions to Nephrology. Vol. 146 2005. p. 143-150 (Contributions to Nephrology; Vol. 146).

Research output: Chapter in Book/Report/Conference proceedingChapter

Tomasoni, S & Benigni, A 2005, The goal of intragraft gene therapy. in Contributions to Nephrology. vol. 146, Contributions to Nephrology, vol. 146, pp. 143-150.
Tomasoni S, Benigni A. The goal of intragraft gene therapy. In Contributions to Nephrology. Vol. 146. 2005. p. 143-150. (Contributions to Nephrology).
Tomasoni, Susanna ; Benigni, Ariela. / The goal of intragraft gene therapy. Contributions to Nephrology. Vol. 146 2005. pp. 143-150 (Contributions to Nephrology).
@inbook{69b54531a200422e9278486ab1056f02,
title = "The goal of intragraft gene therapy",
abstract = "Despite the impressive results of one-year survival rates, organ transplantation still faces major problems. Current anti-rejection drugs reduce systemic immunity nonselectively and increase the risk of infection and cancer on the long term. Theoretically, selective inhibition of alloimmune response can be achieved at the organ level by intragraft transfer of genes with immunomodulatory properties. In the last decade, gene therapy emerged as a new strategy in renal, heart and liver transplantation, showing promising results in experimental animals, almost in controlling acute rejection. The success of gene therapy in the transplant medicine is strongly dependent on the efficiency of the delivery system that allows local transfer and expression of the therapeutic gene in the target organ or tissue. The main findings concerning the suitability of gene therapy in preventing graft rejection will be discussed here.",
author = "Susanna Tomasoni and Ariela Benigni",
year = "2005",
language = "English",
isbn = "3805578563",
volume = "146",
series = "Contributions to Nephrology",
pages = "143--150",
booktitle = "Contributions to Nephrology",

}

TY - CHAP

T1 - The goal of intragraft gene therapy

AU - Tomasoni, Susanna

AU - Benigni, Ariela

PY - 2005

Y1 - 2005

N2 - Despite the impressive results of one-year survival rates, organ transplantation still faces major problems. Current anti-rejection drugs reduce systemic immunity nonselectively and increase the risk of infection and cancer on the long term. Theoretically, selective inhibition of alloimmune response can be achieved at the organ level by intragraft transfer of genes with immunomodulatory properties. In the last decade, gene therapy emerged as a new strategy in renal, heart and liver transplantation, showing promising results in experimental animals, almost in controlling acute rejection. The success of gene therapy in the transplant medicine is strongly dependent on the efficiency of the delivery system that allows local transfer and expression of the therapeutic gene in the target organ or tissue. The main findings concerning the suitability of gene therapy in preventing graft rejection will be discussed here.

AB - Despite the impressive results of one-year survival rates, organ transplantation still faces major problems. Current anti-rejection drugs reduce systemic immunity nonselectively and increase the risk of infection and cancer on the long term. Theoretically, selective inhibition of alloimmune response can be achieved at the organ level by intragraft transfer of genes with immunomodulatory properties. In the last decade, gene therapy emerged as a new strategy in renal, heart and liver transplantation, showing promising results in experimental animals, almost in controlling acute rejection. The success of gene therapy in the transplant medicine is strongly dependent on the efficiency of the delivery system that allows local transfer and expression of the therapeutic gene in the target organ or tissue. The main findings concerning the suitability of gene therapy in preventing graft rejection will be discussed here.

UR - http://www.scopus.com/inward/record.url?scp=16544376027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544376027&partnerID=8YFLogxK

M3 - Chapter

C2 - 15567928

AN - SCOPUS:16544376027

SN - 3805578563

SN - 9783805578561

VL - 146

T3 - Contributions to Nephrology

SP - 143

EP - 150

BT - Contributions to Nephrology

ER -